3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Breast
2
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
Oxaliplatin
1004
Fluorouracil
800
Capecitabine
764
Gemcitabine
650
Leucovorin
559
Irinotecan
537
Bevacizumab
513
Radiotherapy
460
Cisplatin
440
Drug Therapy
298
Cetuximab
280
Surgical Procedures, Operative
229
Paclitaxel
228
S 1 (combination)
217
pembrolizumab
205
Docetaxel
199
130-nm albumin-bound paclitaxel
196
Nivolumab
193
sintilimab
191
Radiosurgery
190
lenvatinib
180
Folfox protocol
179
Sorafenib
178
Albumin-Bound Paclitaxel
173
apatinib
170
tislelizumab
161
camrelizumab
160
Neoadjuvant Therapy
158
Blood Specimen Collection
154
durvalumab
148
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Isoflurane
×
Gastrointestinal
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled